Advertisement
Screener

Bicycle Therapeutics plc (BCYC) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.6 / 5 stars · 37/72 Roast Me

Bicycle Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Bicycle Therapeutics plc (BCYC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-22.

Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-04-22

  • Bicycle Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
  • Bicycle Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
  • Bicycle Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
  • Bicycle Therapeutics plc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-310.00%
DEF 14A · filed 2026-04-22
2024-12-310.00%
10-K · filed 2025-02-25
2023-12-310.00%
10-K · filed 2024-02-20
2022-12-310.00%
10-K · filed 2023-02-28
2021-12-310.00%
10-K · filed 2022-03-01
2020-12-310.00%
10-K · filed 2021-03-11
2019-12-310.00%
10-K · filed 2020-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
GENELUX Corp (GNLX)United States$0.110B-3.83
Equillium, Inc. (EQ)United States$0.109B-11.27
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
ProMIS Neurosciences Inc. (PMN)$0.102B